Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Geranylgeraniol (GG) is a naturally occurring 20-carbon acyclic diterpene alcohol and a key intermediate in the mevalonate pathway, primarily sourced from annatto (*Bixa orellana*). It serves as a metabolic precursor for the synthesis of geranylgeranyl pyrophosphate (GGPP), which is essential for the post-translational geranylgeranylation of small GTPases (such as Rab, Rho, and Ras), the endogenous production of coenzyme Q10 (CoQ10), and the synthesis of menaquinone-4 (Vitamin K2). Clinically, GG is being investigated for its ability to mitigate statin-associated muscle symptoms (myopathy) by bypassing HMG-CoA reductase inhibition to restore depleted GGPP levels. It is also under evaluation for its potential to support healthy testosterone levels in middle-aged adults, improve bone health by modulating osteoblast and osteoclast activity, and address metabolic disruptions in conditions like Mevalonate Kinase Deficiency (MKD) and diabetic neuropathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on geranylgeraniol.